Status of familial hypercholesterolemia among patients with premature coronary artery disease in Vietnam: Results of opportunistic screening strategy
Main Article Content
Abstract
Knowledge about familial hypercholesterolemia is limited in Viet Nam. This study was to assess the effect of opportunistic screening for familial hypercholesterolemia in patients with premature coronary artery disease and clinical characteristics of familial hypercholesterolemia patients. We enrolled 180 patients with premature coronary artery disease from Vietnam National Heart Institute. Phenotypic familial hypercholesterolemia was detected by the Dutch Lipid Clinic Network criteria. Results showed that the prevalence of phenotypic familial hypercholesterolemia among patients with premature coronary artery disease was 8.3%. Most of familial hypercholesterolemia patients were smokers (60%), while tendinous xanthoma and arcus cornealis were also common (46.7% vs 66.7%, respectively). Most of patients with familial hypercholesterolemia had 93.3% of significant coronary artery and carotid artery stenosis (93.3% vs 69.2%, respectively). However, only 26.7% of familial hypercholesterolemia patients were treated with high-intensity statins. In conclusion, the high prevalence of familial hypercholesterolemia in premature coronary artery disease suggests the effect of opportunistic screening. Patients with familial hypercholesterolemia patients had severe atherosclerositic status but were undertreated.
Article Details
Keywords
familial hypercholesterolemia, premature coronary artery disease, opportunistic screening, atherosclerosis, lowering lipid therapy.
References
2. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease : Consensus Statement of the European Atherosclerosis Society. European heart journal. 2013;34(45):3478-3490.
3. Brett T, Qureshi N, Gidding S, Watts GF. Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part. Atherosclerosis. 2018;277:399-406.
4. McGowan MP, Dehkordi SHH, Moriarty PM, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. Journal of the American Heart Association. 2019;8(24):e013225.
5. Sawhney JPS, Prasad SR, Sharma M, et al. Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India. Indian heart journal. 2019;71(2):118-122.
6. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. Circulation. 2011;124(23):2610-2642.
7. Pang J, Poulter EB, Bell DA, et al. Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. Journal of clinical lipidology. 2015;9(5):703-708.
8. Faggiano P, Pirillo A, Griffo R, et al. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. International journal of cardiology. 2018;252:193-198.
9. Williams JK, Anthony MS, Honoré EK, et al. Regression of Atherosclerosis in Female Monkeys. Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15(7):827-836.
10. Inoue T. Cigarette Smoking as a Risk Factor of Coronary Artery Disease and its Effects on Platelet Function. Tob Induc Dis. 2004;2(1):2-2.
11. Shin DG, Han SM, Kim DI, et al. Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis. Atherosclerosis. 2015;243(1):53-58.
12. Maroszyńska-Dmoch EM, Wożakowska-Kapłon B. Clinical and angiographic characteristics of coronary artery disease in young adults: a single centre study. Kardiologia polska. 2016;74(4):314-321.
13. ten Kate GL, ten Kate GJ, van den Oord SC, et al. Carotid plaque burden as a measure of subclinical coronary artery disease in patients with heterozygous familial hypercholesterolemia. The American journal of cardiology. 2013;111(9):1305-1310.
14. Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA. Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. Journal of the American College of Cardiology. 2016;68(3):252-260.
15. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal. 2019;41(1):111-188.